					<a href="#" class="dropdown-item"><span class="text-muted">NE1</span> Candidate drug molecule for age-related diseases </a>
					<a href="#" class="dropdown-item"><span class="text-muted">NE2</span> Maximum acquisition price of £10m </a>
					<a href="#" class="dropdown-item"><span class="text-muted">NE3</span> Proven safe in Phase I trial </a>
					<a href="#" class="dropdown-item"><span class="text-muted">NE4</span> Maximum acquisition price of £5m  </a>
					<a href="#" class="dropdown-item"><span class="text-muted">NE5</span> Maximum acquisition price of £1m </a>
					<a href="#" class="dropdown-item"><span class="text-muted">NE6</span> Efficacy shown in Phase II trial </a>
					<a href="#" class="dropdown-item"><span class="text-muted">NE7</span> New therapies for patients with incurable mitochondrial diseases  </a>
					<a href="#" class="dropdown-item"><span class="text-muted">NE8</span> Access to sufficient drug for patient trials </a>
					<a href="#" class="dropdown-item"><span class="text-muted">NE9</span> Endorsement by reputable clinician or scientist </a>
					<a href="#" class="dropdown-item"><span class="text-muted">WA1</span> Efficacy shown in Phase II trial</a>
					<a href="#" class="dropdown-item"><span class="text-muted">WA2</span> Global rights</a>
					<a href="#" class="dropdown-item"><span class="text-muted">WA3</span> Valuation-enhancing investor story</a>
					<a href="#" class="dropdown-item"><span class="text-muted">WA4</span> Regional rights </a>
					<a href="#" class="dropdown-item"><span class="text-muted">WA5</span> Publication rights</a>